Condition
Hyperaldosteronism clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Hyperaldosteronism clinical trials that are recruiting, at sites in 5 countries (most in China (2), Norway (1), United States (1)). 1 was first registered in the last 30 days. By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 1New in 30 days
- 5Countries
Newest Hyperaldosteronism clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital | — | Modena, Modena | Recruiting | Nov 5, 2026 |
| Targeted adrenal artery embolization versus oral spironolactone for idiopathic hyperaldosteronism | — | Beijing, Beijing Municipality and 2 other locations | Recruiting | Jan 9, 2026 |
| Aldosterone-hybrid test to guide curable treatment for primary aldosteronism | — | Singapore, Singapore and 5 other locations | Recruiting | Dec 22, 2025 |
| Adrenal vein sampling in China | — | Hefei, Anhui and 75 other locations | Recruiting | Nov 26, 2025 |
| Evaluating adrenal gland function using a new imaging agent in patients with hormone-related conditions | Phase 2 | Bethesda, Maryland | Recruiting | Feb 7, 2024 |
| Understanding primary aldosteronism in patients from Western Norway | — | Bergen and 1 other locations | Recruiting | Jul 14, 2016 |
All recruiting trials (6)
-
Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital
This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.
-
Targeted adrenal artery embolization versus oral spironolactone for idiopathic hyperaldosteronism
This trial will test whether a minimally invasive targeted adrenal artery embolization works as well as the oral drug spironolactone for people aged 15–60 with idiopathic hyperaldosteronism.
-
Aldosterone-hybrid test to guide curable treatment for primary aldosteronism
This trial tests whether non-invasive biomarkers plus CT imaging can identify unilateral primary aldosteronism and reduce the need for adrenal vein sampling in patients considered for surgery.
-
Adrenal vein sampling in China
This project tests whether different adrenal venous sampling techniques and AVS-guided management help people with primary aldosteronism get better long-term blood pressure and hormone results.
-
Evaluating adrenal gland function using a new imaging agent in patients with hormone-related conditions
This study is testing a new imaging agent to see if it can help find adrenal tumors in adults with hormone-related conditions like hyperaldosteronism or hypercortisolism.
-
Understanding primary aldosteronism in patients from Western Norway
This study is looking to learn more about patients with primary aldosteronism in Western Norway by checking their heart health before and after treatment and comparing it to healthy individuals.
Related topics
Quick answers
How many Hyperaldosteronism clinical trials are recruiting right now?
6, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in China (2 trials), Norway (1 trial), United States (1 trial), Italy (1 trial), Singapore (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.